StockData
Cullinan Therapeutics, Inc. logo

Cullinan Therapeutics, Inc. (CGEM) stock

CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$9.01−0.27 (-2.86%)

Close on Nov 18, 2026Market cap $579.84MP/E –Yield –

Cullinan Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Cullinan Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$175.80M. For fiscal 2025 it was -$175.80M. The highest annual figure on record is -$29.78M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$175.80M–
FY2024Dec 31, 2024-$145.30M–
FY2023Dec 31, 2023-$134.48M–
FY2022Dec 31, 2022-$127.80M–
FY2021Dec 31, 2021-$43.43M–
FY2020Dec 31, 2020-$29.78M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$38.12M–
Q4 FY2024Dec 31, 2024-$36.63M–
Q3 FY2024Sep 30, 2024-$34.14M–
Q2 FY2024Jun 30, 2024-$36.29M–
Q1 FY2024Mar 31, 2024-$38.25M–
Q4 FY2023Dec 31, 2023-$18.13M–
Q3 FY2023Sep 30, 2023-$34.14M–
Q2 FY2023Jun 30, 2023-$31.06M–
Q1 FY2023Mar 31, 2023-$51.16M–
Q4 FY2022Dec 31, 2022-$25.87M–
Q3 FY2022Sep 30, 2022-$54.60M–
Q2 FY2022Jun 30, 2022-$25.42M–
Q1 FY2022Mar 31, 2022-$21.91M–
Q4 FY2021Dec 31, 2021-$15.17M–
Q4 FY2020Dec 31, 2020-$9.44M–
Q3 FY2020Sep 30, 2020-$9.08M–
Q2 FY2020Jun 30, 2020-$6.25M–
Q1 FY2020Mar 31, 2020-$5.02M–

More Cullinan Therapeutics figures

See a number that looks wrong?